{"id":137409,"date":"2025-03-18T16:54:49","date_gmt":"2025-03-18T20:54:49","guid":{"rendered":"https:\/\/wfh.org\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/"},"modified":"2025-03-26T10:07:18","modified_gmt":"2025-03-26T14:07:18","slug":"takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate","status":"publish","type":"post","link":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/","title":{"rendered":"Takeda va cesser la production des m\u00e9dicaments pour l\u2019h\u00e9mophilie HEMOFIL M et RECOMBINATE"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"137409\" class=\"elementor elementor-137409 elementor-136506\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-55a6412 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"55a6412\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-cf8dfc7\" data-id=\"cf8dfc7\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2ad981a elementor-widget elementor-widget-text-editor\" data-id=\"2ad981a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.23.0 - 25-07-2024 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p>Takeda a inform\u00e9 la F\u00e9d\u00e9ration mondiale de l\u2019h\u00e9mophilie (FMH) que cette d\u00e9cision \u00e9tait motiv\u00e9e par le fait que les personnes atteintes d\u2019un trouble de la coagulation se tournent vers des th\u00e9rapies alternatives, notamment celles que propose le groupe Takeda lui-m\u00eame. L\u2019entreprise souligne \u00e9galement que cet arr\u00eat n\u2019est pas d\u00fb \u00e0 des pr\u00e9occupations li\u00e9es \u00e0 la qualit\u00e9 ou \u00e0 la s\u00e9curit\u00e9, car les deux produits restent efficaces et conformes aux normes de r\u00e9glementation.<\/p>\n<p>La FMH a bien conscience que cette transition vers d\u2019autres produits peut pr\u00e9senter des difficult\u00e9s. Takeda d\u00e9clare contacter activement les professionnel\u00b7les de sant\u00e9 et les organisations nationales membres (ONM) dans les pays concern\u00e9s afin d\u2019accompagner la transition. L\u2019entreprise continuera \u00e0 fournir les produits aux patient\u00b7es qui les utilisent encore jusqu\u2019\u00e0 ce que le stock soit \u00e9puis\u00e9 ou expire (\u00e0 la mi-2026), le d\u00e9lai exact \u00e9tant soumis \u00e0 la demande et \u00e0 l\u2019efficacit\u00e9 du produit. Les th\u00e9rapies alternatives devraient \u00eatre en mesure de r\u00e9pondre \u00e0 la demande en HEMOFIL M et RECOMBINATE, et nous esp\u00e9rons que les membres de notre communaut\u00e9 pourront les adopter le plus rapidement possible.<\/p>\n<p>Nous encourageons les ONM qui souhaitent en savoir plus, ou qui ont besoin d\u2019une aide suppl\u00e9mentaire dans l\u2019abandon de HEMOFIL M et RECOMBINATE, \u00e0 contacter leur responsable r\u00e9gional\u00b7e. Les personnes atteintes d\u2019un trouble de la coagulation qui ont des inqui\u00e9tudes peuvent contacter leur ONM.<\/p>\n<p>Pour en savoir plus, lisez la lettre int\u00e9grale de Takeda <a href=\"https:\/\/wfh.org\/wp-content\/uploads\/2025\/03\/Takeda-HEMOFIL-M-and-RECOMBINATE-18-March-2025-V3.pdf\" target=\"_blank\" rel=\"noopener\">ici<\/a> (en anglais).<\/p>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Takeda a annonc\u00e9 l\u2019arr\u00eat mondial de la production de ses traitements de l\u2019h\u00e9mophilie A, HEMOFIL\u00ae M (facteur anti-h\u00e9mophilique (humain), m\u00e9thode M, monoclonal purifi\u00e9) et RECOMBINATE (facteur VIII de coagulation recombinant, octocog alfa). <\/p>\n","protected":false},"author":13,"featured_media":30514,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[197,34],"tags":[],"search-category":[85],"class_list":["post-137409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-declarations-publiques-et-recommandations-de-la-fmh","category-wfh-statements-and-advisories","search-category-article"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.4 (Yoast SEO v23.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Takeda va cesser la production des m\u00e9dicaments pour l\u2019h\u00e9mophilie HEMOFIL M et RECOMBINATE | FMH - F\u00e9d\u00e9ration mondiale de l\u2019h\u00e9mophilie<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda va cesser la production des m\u00e9dicaments pour l\u2019h\u00e9mophilie HEMOFIL M et RECOMBINATE\" \/>\n<meta property=\"og:description\" content=\"Takeda a annonc\u00e9 l\u2019arr\u00eat mondial de la production de ses traitements de l\u2019h\u00e9mophilie A, HEMOFIL\u00ae M (facteur anti-h\u00e9mophilique (humain), m\u00e9thode M, monoclonal purifi\u00e9) et RECOMBINATE (facteur VIII de coagulation recombinant, octocog alfa).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/\" \/>\n<meta property=\"og:site_name\" content=\"FMH - F\u00e9d\u00e9ration mondiale de l\u2019h\u00e9mophilie\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/wfhemophilia\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T20:54:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-26T14:07:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-FR.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2501\" \/>\n\t<meta property=\"og:image:height\" content=\"1459\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mitch Semienchuk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mitch Semienchuk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/\"},\"author\":{\"name\":\"Mitch Semienchuk\",\"@id\":\"https:\/\/wfh.org\/fr\/#\/schema\/person\/f57928f0dd0ca8906b81082895256d8f\"},\"headline\":\"Takeda va cesser la production des m\u00e9dicaments pour l\u2019h\u00e9mophilie HEMOFIL M et RECOMBINATE\",\"datePublished\":\"2025-03-18T20:54:49+00:00\",\"dateModified\":\"2025-03-26T14:07:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/\"},\"wordCount\":281,\"publisher\":{\"@id\":\"https:\/\/wfh.org\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-FR.png\",\"articleSection\":[\"D\u00e9clarations publiques et recommandations de la FMH\",\"WFH statements and advisories\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/\",\"url\":\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/\",\"name\":\"Takeda va cesser la production des m\u00e9dicaments pour l\u2019h\u00e9mophilie HEMOFIL M et RECOMBINATE | FMH - F\u00e9d\u00e9ration mondiale de l\u2019h\u00e9mophilie\",\"isPartOf\":{\"@id\":\"https:\/\/wfh.org\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-FR.png\",\"datePublished\":\"2025-03-18T20:54:49+00:00\",\"dateModified\":\"2025-03-26T14:07:18+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/#primaryimage\",\"url\":\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-FR.png\",\"contentUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-FR.png\",\"width\":2501,\"height\":1459,\"caption\":\"lgoo\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/wfh.org\/fr\/#website\",\"url\":\"https:\/\/wfh.org\/fr\/\",\"name\":\"FMH - F\u00e9d\u00e9ration mondiale de l\u2019h\u00e9mophilie\",\"description\":\"WFH - World Federation of Hemophilia\",\"publisher\":{\"@id\":\"https:\/\/wfh.org\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/wfh.org\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/wfh.org\/fr\/#organization\",\"name\":\"World Federation of Hemophilia\",\"url\":\"https:\/\/wfh.org\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/wfh.org\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg\",\"contentUrl\":\"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg\",\"width\":210,\"height\":63,\"caption\":\"World Federation of Hemophilia\"},\"image\":{\"@id\":\"https:\/\/wfh.org\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/wfhemophilia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/wfh.org\/fr\/#\/schema\/person\/f57928f0dd0ca8906b81082895256d8f\",\"name\":\"Mitch Semienchuk\",\"sameAs\":[\"analytics\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda va cesser la production des m\u00e9dicaments pour l\u2019h\u00e9mophilie HEMOFIL M et RECOMBINATE | FMH - F\u00e9d\u00e9ration mondiale de l\u2019h\u00e9mophilie","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/","og_locale":"fr_FR","og_type":"article","og_title":"Takeda va cesser la production des m\u00e9dicaments pour l\u2019h\u00e9mophilie HEMOFIL M et RECOMBINATE","og_description":"Takeda a annonc\u00e9 l\u2019arr\u00eat mondial de la production de ses traitements de l\u2019h\u00e9mophilie A, HEMOFIL\u00ae M (facteur anti-h\u00e9mophilique (humain), m\u00e9thode M, monoclonal purifi\u00e9) et RECOMBINATE (facteur VIII de coagulation recombinant, octocog alfa).","og_url":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/","og_site_name":"FMH - F\u00e9d\u00e9ration mondiale de l\u2019h\u00e9mophilie","article_publisher":"https:\/\/www.facebook.com\/wfhemophilia\/","article_published_time":"2025-03-18T20:54:49+00:00","article_modified_time":"2025-03-26T14:07:18+00:00","og_image":[{"width":2501,"height":1459,"url":"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-FR.png","type":"image\/png"}],"author":"Mitch Semienchuk","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Mitch Semienchuk","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/#article","isPartOf":{"@id":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/"},"author":{"name":"Mitch Semienchuk","@id":"https:\/\/wfh.org\/fr\/#\/schema\/person\/f57928f0dd0ca8906b81082895256d8f"},"headline":"Takeda va cesser la production des m\u00e9dicaments pour l\u2019h\u00e9mophilie HEMOFIL M et RECOMBINATE","datePublished":"2025-03-18T20:54:49+00:00","dateModified":"2025-03-26T14:07:18+00:00","mainEntityOfPage":{"@id":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/"},"wordCount":281,"publisher":{"@id":"https:\/\/wfh.org\/fr\/#organization"},"image":{"@id":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/#primaryimage"},"thumbnailUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-FR.png","articleSection":["D\u00e9clarations publiques et recommandations de la FMH","WFH statements and advisories"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/","url":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/","name":"Takeda va cesser la production des m\u00e9dicaments pour l\u2019h\u00e9mophilie HEMOFIL M et RECOMBINATE | FMH - F\u00e9d\u00e9ration mondiale de l\u2019h\u00e9mophilie","isPartOf":{"@id":"https:\/\/wfh.org\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/#primaryimage"},"image":{"@id":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/#primaryimage"},"thumbnailUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-FR.png","datePublished":"2025-03-18T20:54:49+00:00","dateModified":"2025-03-26T14:07:18+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/wfh.org\/fr\/article\/takeda-va-cesser-la-production-des-medicaments-pour-lhemophilie-hemofil-m-et-recombinate\/#primaryimage","url":"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-FR.png","contentUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2022\/03\/WFH-statement-News-FR.png","width":2501,"height":1459,"caption":"lgoo"},{"@type":"WebSite","@id":"https:\/\/wfh.org\/fr\/#website","url":"https:\/\/wfh.org\/fr\/","name":"FMH - F\u00e9d\u00e9ration mondiale de l\u2019h\u00e9mophilie","description":"WFH - World Federation of Hemophilia","publisher":{"@id":"https:\/\/wfh.org\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wfh.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/wfh.org\/fr\/#organization","name":"World Federation of Hemophilia","url":"https:\/\/wfh.org\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/wfh.org\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg","contentUrl":"https:\/\/wfh.org\/wp-content\/uploads\/2021\/10\/WFH-LOGO-ENGLISH.svg","width":210,"height":63,"caption":"World Federation of Hemophilia"},"image":{"@id":"https:\/\/wfh.org\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/wfhemophilia\/"]},{"@type":"Person","@id":"https:\/\/wfh.org\/fr\/#\/schema\/person\/f57928f0dd0ca8906b81082895256d8f","name":"Mitch Semienchuk","sameAs":["analytics"]}]}},"_links":{"self":[{"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/posts\/137409"}],"collection":[{"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/comments?post=137409"}],"version-history":[{"count":1,"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/posts\/137409\/revisions"}],"predecessor-version":[{"id":137410,"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/posts\/137409\/revisions\/137410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/media\/30514"}],"wp:attachment":[{"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/media?parent=137409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/categories?post=137409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/tags?post=137409"},{"taxonomy":"search-category","embeddable":true,"href":"https:\/\/wfh.org\/fr\/wp-json\/wp\/v2\/search-category?post=137409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}